European Commission eyes pharma ethics
September 27, 2010Research and Development, Sales and Marketing European Commission, corporate responsibility, ethics
The European Commission is to examine corporate responsibility in the pharmaceutical industry with the aim of developing a series of …
Late stage cancer drug failure for AstraZeneca
September 27, 2010Sales and Marketing AstraZeneca, prostate cancer, zibotentan
AstraZeneca’s oncology pipeline has suffered a further blow after prostate cancer drug zibotentan failed to meet its primary endpoint of …
AZ’s antiplatelet recommended for European approval
September 27, 2010Sales and Marketing Brilinta, Brilique, Brillinta, Possia
AstraZeneca’s oral antiplatelet treatment Brilique has received a positive opinion from a key European advisory committee. A marketing authorisation for …
Glass flakes lead Amgen to order Epogen and Procrit recall
September 27, 2010Manufacturing and Production Amgen, Centocor Ortho Biotech, Epogen, Procrit, manufacturing compliance, recalls
Amgen has taken what it describes as a precautionary measure and recalled lots of two of its erythropoietin-based products Epogen …
Andy Black reappointed as Kinapse Chief Executive
September 27, 2010Kinapse
27 September, 2010London, UK Andy Black reappointed as Kinapse Chief Executive The Board of Directors of Kinapse Ltd. today …
Dr Alan Palmer joins One Nucleus
September 27, 2010Research and Development One Nucleus, apppointment, research and development
Cambridge, UK-based life sciences body One Nucleus has appointed Dr Alan Palmer as a director. Alan is co-founder and chief …
Kinapse CEO stepping down
September 24, 2010Kinapse
24 September, 2010London, UKThe Board of Directors of Kinapse Ltd. today announced that Co-founder Shalabh Kumar has stepped down as …
Matthew Newman joins Incuna
September 24, 2010Medical Communications Incuna, appointment, medical communications
Oxford, UK-based digital healthcare agency Incuna has appointed Matthew Newman as creative director.Matthew will oversee the creative department at Incuna, …
Europe committee rejects MS treatment Movectro
September 24, 2010Sales and Marketing Cladribine, Merck Serono Movectro
The Europe Medicines Agency has rejected Merck Serono’s new multiple sclerosis treatment Movectro, saying its benefits do not outweigh its …
Gene-targeting asthma drugs within a decade
September 24, 2010Research and Development asthma, genetic
Asthma treatments that target genetic variants found in people susceptible to the condition could be available within the next ten …
Novartis sells bladder treatment rights to Warner Chilcott
September 24, 2010Sales and Marketing Enablex, Novartis, Warner Chilcott
Novartis is to sell the US rights to market its overactive bladder treatment Enablex to Warner Chilcott. Novartis will receive …
Woolley Pau appoints senior creative
September 24, 2010Medical Communications Woolley Pau, appointment, medical communications
Iain Harrison has joined Woolley Pau as deputy creative director, bringing 24 years industry experience to the agency in a …
Avandia withdrawn in Europe, but remains in US
September 24, 2010Sales and Marketing Avandia, FDA, pharmacovigilance, safety
GSK’s diabetes drug Avandia is to be withdrawn from the market in Europe because of high levels of heart attack, …
Digital Pharma: Janssen unveils UK social media plans
September 23, 2010Medical Communications Digital Pharma blog, Facebook, Janssen, Twitter, psoriasis, social media, youtube
Janssen UK is to launch a wide-ranging social media campaign to raise awareness of the chronic skin condition psoriasis. The …
Extra phase II studies boost GSK’s Relovair
September 23, 2010COPD, GlaxoSmithKline, Relovair, asthma
GlaxoSmithKline has conducted additional phase II trials on its asthma/COPD drug Relovair to answer a number of safety and efficacy …
FDA committee backs Pradaxa
September 23, 2010Sales and Marketing Boehringer, Pradaxa, atrial fibrilation
An FDA committee has voted unanimously in favour of approving Pradaxa for stroke prevention in patients with atrial fibrillation. The …
Solid results for AstraZeneca’s oral RA drug
September 23, 2010Research and Development AstraZeneca, Rigel, fostamatinib, rheumatoid arthritis
AstraZeneca’s new oral treatment for rheumatoid arthritis has produced solid results in a phase II trial. Fostamatinib is the first …
Lilly names new VP of communications
September 23, 2010Medical Communications appointment, lilly, medical communications
Jeffrey Winton will next month join Lilly as vice president of communications and take a place on the company’s global …
Gilenya approved as new frontline MS treatment
September 22, 2010Research and Development, Sales and Marketing Cladribine, FDA, Novartis, gilenya
Novartis’ new multiple sclerosis treatment Gilenya has been approved by the FDA, and is set to significantly alter the way …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
